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Abstract
Background Aneurysmal subarachnoid haemorrhage (aSAH)
is a haemorrhagic form of stroke and occurs in a younger
population compared with ischaemic stroke or intracerebral
haemorrhage. It accounts for a large proportion of productive
life-years lost to stroke. Its surgical and medical treatment
represents a multidisciplinary effort. Due to the complexity
of the disease, the management remains difficult to standard-
ise and quality of care is accordingly difficult to assess.
Objective To create a registry to assess management param-
eters of patients treated for aSAH in Switzerland.
Methods A cohort study was initiated with the aim to record
characteristics of patients admitted with aSAH, starting
January 1st 2009. Ethical committee approval was obtained
or is pending from the institutional review boards of all
centres. In the study period, seven Swiss hospitals (five
university [U], two non-university medical centres) harbour-
ing a neurosurgery department, an intensive care unit and an
interventional neuroradiology team so far agreed to partici-
pate in the registry (Aarau, Basel [U], Bern [U], Geneva [U],
Lausanne [U], St. Gallen, Zürich [U]). Demographic and
clinical parameters are entered into a common database.
Discussion This database will soon provide (1) a nation-
wide assessment of the current standard of care and (2) the
outcomes for patients suffering from aSAH in Switzerland.
Based on data from this registry, we can conduct cohort
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comparisons or design diagnostic or therapeutic studies on a
national level. Moreover, a standardised registration system
will allow healthcare providers to assess the quality of care.
Keywords Subarachnoid haemorrhage . Intracranial
aneurysm . Cerebral aneurysm
Introduction
Overview and socioeconomic impact
SAH is a type of haemorrhagic stroke, which occurs due to
rupture of an intracranial aneurysm in 85 % of cases. The
incidence of aSAH between regions of the world is highly
variable (from 3 in parts of South America to over 20 per
100,000 person-years in Japan) [3]. aSAH represents 5 % of
all cerebrovascular accidents. In contrast to the more prev-
alent ischaemic stroke and intracerebral haemorrhage which
affect older age-groups, half of the patients suffering from
aSAH are younger than 55 years. aSAH thus accounts for a
quarter of all productive life years lost to stroke [11].
Patients admitted and diagnosed with aSAH have long hos-
pital stays (average in patients over 65 years: 22 days [18])
and most are at least temporarily monitored in a neuro-
intensive care unit. The cost of hospitalisation of a “low
severity” case of aSAH was estimated to be 35,000$ in the
US [14]. An estimated 437 million EUR are spent per year
on the treatment of aSAH in Germany alone [4]. In addition
to the socioeconomic impact, the disease affects the quality
of life of more than nine out of ten patients even 1 year after
discharge [15].
Necessity of a nationwide registry
The management of aSAH in Switzerland has not been
assessed on a national level to date. We united large neuro-
vascular centres in Switzerland to create a registry for
aSAH. This registry helps collect clinical and management
data from different centres and pools it in one common
database. It may provide referring caregivers and healthcare
providers with a critical tool to assess the quality of care in a
disease which has a high socio-economic burden. Moreover,
it may serve as a tool to foster scientific collaboration and
address a number of remaining questions about the manage-
ment of aSAH in the future.
Regarding SAH, data from the federal statistics bureau of
Switzerland are based strictly on ICD-10 codes provided by
hospitals and show an estimate of 13 per 100,000 in a
population of roughly 8 million (http://bfs.admin.ch). These
numbers, however, are not referring to aneurismal SAH
exclusively and thus exceed the numbers which we expect
to obtain. In the first years of the registry we cannot claim
complete recruitment of SAH patients throughout Switzer-
land, and the goal is therefore that assessment of incidence
will be performed later on.
Dilemmas in the management of aSAH
Aneurysmal SAH has a poor prognosis, with a mortality of
about 40 % and morbidity including neurological deficits
affecting about one-third of patients. Prognosis is not only
limited by the bleed itself with the associated early brain
injury but also by conditions such as hydrocephalus,
delayed ischaemic neurological deficits and extracranial
disease [13]. The following points briefly illustrate exem-
plary domains where further large-scale studies are neces-
sary to answer imminent questions on the optimal
management of aSAH. These and other points have been
included in the current registry.
Aneurysm treatment
Rebleeding is the most dangerous complication of aSAH and
occurs mostly within hours or days of the initial bleed. There-
fore, it is mandatory to perform aneurysm treatment early to
prevent re-rupture. The main options for aneurysm occlusion
are surgical clipping and endovascular therapy. The treatment
decision is commonly taken after interdisciplinary discussion
based on aneurysm size, location and the patient’s constitu-
tion. Surgical as well as interventional techniques have under-
gone significant development in recent years, prompting a
continuous critical assessment of safety, efficacy and long-
term outcome. Stents as endovascular flow diverters have
recently expanded our treatment options in selected cases of
aneurysms. Comparison between these rapidly evolving tech-
niques has become increasingly difficult.
Management of hydrocephalus
About 15 % of patients develop acute hydrocephalus after
aSAH [8]. The standard treatment for acute hydrocephalus
is cerebrospinal fluid drainage by an external ventricular
drain. However, recent studies have re-assessed the possi-
bility of lumbar drainage. The optimal management of sub-
acute or late hydrocephalus still remains a matter of debate.
Uncertainty also remains about the best timing to perform
surgery for a ventriculo-peritoneal shunt versus trying re-
peated lumbar punctures.
Detection of delayed ischaemic neurological deficit
Delayed ischaemic neurological deficits occur in a signifi-
cant proportion of patients after aSAH and CT-proven
infarcts occur in 40 % [16]. It is suspected that the number
of patients suffering cerebral ischaemia after aSAH has been
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underestimated. Both the prevention, detection and the treat-
ment of delayed ischaemia remain unsolved problems. A
number of diagnostic bedside methods for continuous mon-
itoring of cerebral blood flow, oxygenation and metabolism
are available, but their respective limitations have hitherto
prevented universal acceptance [10, 19]. Potential draw-
backs include a small sample volume and the inability to
monitor cerebral blood flow directly. Measurements are
often limited to a small sample volume with the potential
risk of missing cerebral ischaemia in other vascular territo-
ries. Moreover, recent insights into alterations of cerebral
blood flow in response to waves of cortical depolarisation as
precursors of ischaemia may improve the early detection of
delayed ischaemic events. However, the development of
practicable and widely available monitoring equipment is
still in the experimental stages [6]. Future approaches using
advanced bioinformatics may be required for applying
multi-parameter monitoring to clinical care [9].
Prevention of delayed ischaemic neurological deficits
The fact that delayed ischaemia after aSAH occurs several
days after the bleed in patients who are already in the
hospital makes this complication potentially preventable.
Most of the early efforts in preventing these deficits were
aimed at the treatment of angiographic cerebral vasospasm
which occurs between days 4 and 14 of SAH. Interestingly,
the reduction of angiographic vasospasm has so far not
translated to an improvement in patient outcome [12]. The
calcium-channel blocker nimodipine has a modest impact
on delayed cerebral ischaemia and is the only pharmaceuti-
cal treatment approved for the treatment of delayed cerebral
ischaemia and vasospasm [5]. However, its side effects,
particularly systemic hypotension, significantly limit its
use in this patient population where therapeutic hyperten-
sion is mandatory. Local delivery of vasodilators such as
nicardipine pellets was found to be of benefit in patients
undergoing surgery for aSAH [2]. While interventional bal-
loon dilation or injection of vasodilatory substances for
symptomatic vasospasm are established procedures, their
timing and risks are debatable. Prophylactic angioplasty
has not improved outcome [21].
Outcome measures
Aneurysmal SAH for the larger part affects people in their
working age. Therefore, even slight neurological disturban-
ces can have a major impact on their ability to return to their
previous occupation. Some authors argued that the pre-
sumed lack of efficacy for drugs reversing delayed cerebral
vasospasm may be due to the absence of adequate outcome
measures. Such outcome measures include a thorough neu-
rological test battery as well as quality of life parameters. A
registry on a national level could have a sufficient caseload
to help develop and validate testing batteries including
quality of life questionnaires such as the modified Rankin
Scale or the Glasgow Outcome Scale Extended [20]. Our
hope is also that by standardising outcome measures at a
later point in this study, follow-up will ultimately improve.
Materials and methods
Neurovascular teams at seven Swiss hospitals (five university
[U], two non-university medical centres) which treat patients
with aSAH held two initiation meetings in 2009 and 2010
(Aarau, Basel [U], Bern [U], Geneva [U], Lausanne [U], St.
Gallen, Zürich [U]). Participating centres have a neurosurgery
department, an intensive care unit and an endovascular team
and are tertiary referral centres within Switzerland. The Swiss
SOS registry is designed as a multicentre database with the
same parameters (an overview is provided in Table 1) which
each participating centremanages independently. Due tomiss-
ing values in this preliminary sample from the feasibility
period, not all patients had complete data sets, resulting in
an occasionally lower number of totals. Anonymous demo-
graphic and clinical data are recorded for all patients with
aSAH for a permanent data collection. Where necessary, this
is done retrospectively for cases admitted since 01.01.2009.
Ethical committee approval was obtained or is pending from
the institutional review boards of all centres.
Patient recruitment/inclusion and exclusion criteria
Inclusion criteria: All patients admitted with a diagnosis of
aSAH at one of the participating centres are entered into the
local database. Residents from outside Switzerland can
therefore be accepted for treatment in Switzerland and
vice-versa. This fluctuation was not quantified as the goal
of the database was to unify assessment of SAH manage-
ment in Switzerland, regardless of the patients’ origin.
Patient data are anonymous. The local databases can be
fused into a common centralised file.
Exclusion criteria: Patients in whom the source of haemor-
rhage could not be identified (angiogram-negative SAH) or
SAH with other causes than cerebral aneurysms.
The clinical data of the main hospitalisation (time-point
of SAH) represents the central part of the database. Some
preliminary data from the feasibility assessment period in
2009 is presented in Table 2 to provide an overview on the
demographic and clinical status of patients admitted with
SAH in Switzerland. Data on clinical status at follow-up can
be entered for up to year 5 post SAH. Individual length of
follow-up for patients with aSAH remains at the discretion
of each centre.
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Statistical analysis
Statistical analysis and data quality evaluation will be performed
by a dedicated statistician.
Discussion
Our aim is to create an observational database on clin-
ical management aspects of aSAH. The severity of the
disease and its many complications make aSAH a chal-
lenging disease to treat from the first day to the day
where the patient can leave the hospital, often weeks
later. aSAH patients can be categorised by clinical status
at admission (World Federation of Neurological Sur-
geons Scale [17]), severity of haemorrhage (Fisher scale
[7]), aneurysm localisation, presence of hydrocephalus,
epilepsy or even extracranial disease (e.g. cardiac ar-
rhythmia, pulmonary oedema). While all participating
Swiss centres have a “high volume” [1] with more than
20 patients per year, each patient requires individualised
decision-making based on a multitude of parameters.
Moreover, the patient is treated by a team including among
others neurosurgeons, neuro-interventionalists, neuro-
intensivists and anaesthesiologists. The evident lack of con-
sensus on optimal management prompts a large-scale effort
which cannot be mustered by one centre alone. For a popula-
tion of about 8 million, Switzerland has several neurovascular
centres with a high standard, and a common Swiss registry can
serve multiple purposes:
Assessment of the status quo
The management of patients with aSAH in Switzerland has
not yet been explored on a national level. A common data-
base will help provide such an assessment.
Table 1 Simplified overview of
basic parameters Demographics Unique ID …….…. Age at ictus …….…
Sex: female … male … Tobacco use …
Date and time of… Ictus …….………. Admission …….……….
ICU days …….………. Discharge home …….……….
Admission status Glasgow Coma Scale …… Intubated/sedated ……
Neurological deficit … Pupil status ……
Imaging SAH blood distribution Fisher grade …….….
Aneurysm localisation + type …….……………………………..
Largest diameter (mm) …… Aneurysm side …….….
Other aneurysms …….……………………………..
Treatment Aneurysm: Coil …… Clip …… Stent ……
Hydrocephalus: Ventriculostomy ……
Lumbar drain ……
Ventriculoperitoneal shunt ……
Other: Craniectomy ……
Haematoma removal ……
Vasospasm Delayed neurol. deficit …… Balloon dilation ……
Outcome At discharge, 1 year, 5 years Neurological deficit ……
Modified Rankin ……
Glasgow Outcome Scale ……
Table 2 Overview on preliminary pilot data from 2009
n %
Age (years; median, range) 55 (17–87)
Sex Female 187 67.3 %
Male 91 33.7 %
Clinical status at admission
(Glasgow Coma Scale)
GCS 15 111 40.5 %
GCS 13–14 68 24.8 %
GCS 7–12 30 11.0 %
GCS 3–7 65 23.7 %
Aneurysm treatment Clip 115 42.9 %
Coil 105 39.2 %
Clip + coil 12 4.5 %
Coil + stent 6 2.2 %
Stent 4 1.5 %
None 26 9.7 %
Outcome at discharge
(modified Rankin scale)
0: No symptoms 32 13.3 %
1: No disability (dis.) 70 29.2 %
2: Slight dis. 45 18.8 %
3: Moderate dis. 31 12.9 %
4: Moderately severe dis. 30 12.5 %
5: Severe dis. 24 10.0 %
6: Dead 40 16.7 %
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Simplicity and standardisation
Our aim is to provide a database on aSAH which has a
limited number of parameters and remains simple in its use.
The parameters should be applicable in a similar manner by
investigators from all centres and are therefore standardised.
Socioeconomic parameters and patient outcome
Age, duration of hospitalisation (total duration and intensive
care unit) and modified Rankin Scale at discharge as well as at
follow-up are recorded in the database and give an estimate of
the immediate socioeconomic burden of aSAH.Moreover, the
database can be extended using quality of life measures.
Clinical status and management
Basic information on clinical status at admission, treatment
modalities as well as delayed complications are recorded.
The presence of multiple aneurysms and their impact on
management can be derived from the datasets.
Quality of care
In response to increasing medical knowledge, medical dis-
ciplines are increasingly evolving towards areas of subspe-
cialty. This tendency is also tangible in Switzerland where
federal efforts are focused towards developing reference
centres which are staffed and equipped appropriately and
which will receive patients with a specific pathology from
beyond their traditional recruitment area.
Healthcare providers are also asked to justify expenses by
documenting the quality of care. The ability to provide out-
comes in a standardised manner will enable clinicians to
anticipate requests of insurers and public institutions. This is
particularly important since the costs of neurointensive care
management are high and medical evidence is often lacking
to support our individual-based treatment decisions.
Critical mass for research and further studies
Swiss neurovascular centres traditionally have shown a
strong interest in the improvement of patient care through
scientific research. To unite several high-level neurovascular
centres may improve the visibility of a geographically lim-
ited community with similar research interests. The coordi-
nation for larger-scale studies or translational research
efforts could be facilitated.
Funding
Currently, the Swiss SOS is a loose framework of a “neuro-
vascular interest group”. At present, no funding was applied
for. As the first results of the collaboration will surface,
hypotheses for potential scientific applications will be dis-
cussed and funding will be applied for to answer specific
questions or conduct a project of common interest.
Limitations
At the beginning, our database will be retrospective and
observational. The assessed parameters (provided in Table 1)
are of relative simplicity in order to limit time and expenses
for the investigators. In the first phase of the project, there
will be no study nurse in the majority of centres due to the
lack of starting funds as described above. Each centre has
assigned a physician who is responsible for quality clear-
ance before data submission to the registry.
Conclusion
The creation of a national network for aSAH is a logical step
forward in documenting treatment and outcome for a com-
plex disease. The first goal is the improvement of patient
management by standardisation and comparability. Further-
more, the registry may serve as an initiator for studies with
scientific hypotheses regarding diagnosis and treatment of
aSAH.
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Comment
Here we have a useful and erudite discussion of the natural history and
management issues in aSAH patients, framed in a prospective registry
that the authors have developed for major Swiss neurosurgical units.
The discussion of the registry is of course theoretical at present as there
are no data yet. The potential value of the information is great, and the
feasibility of acquiring useful data is high since the country is a small
one and all of the major units have been recruited to collaborate.
Certainly we would have more difficulty with such a project in the
USA, where aSAH care is delivered in many ways in many centres
with great variance in management styles.
We look forward with anticipation to a broad comprehensive sam-
ple and the acquisition of quality information regarding the clinical
issues that challenge us all, including best primary treatment option for
optimised outcomes, prevalence of hydrocephalus, best management
strategies for DIND, and the like. If the dataset is comprehensive, as we
hope it will be, even questions that are not currently framed can be
addressed in later years by accessing the sample. As the authors have
pointed out, the registry also lends itself well to assessment and
documentation of quality, and if properly managed, will be a good tool
for prominent neurosurgeons (the investigators) to influence and shape
payer and government policies regarding the management of these
resource intense high-consumption patients.
Christopher Miranda Loftus
Philadelphia, USA
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